No Data
Zhejiang Medicine's (SHSE:600216) Earnings Are Of Questionable Quality
Zhejiang Medicine's H1 Profit Jumps 16% on Higher Operating Income
Summary of Zhejiang Medicine's 2024 semi-annual report
Zhejiang Medicine's semi-annual report for 2024.
Zhejiang Medicine (600216.SH) released its performance for the first half of the year, with a net income of 0.315 billion yuan, a year-on-year increase of 15.82%.
Zhejiang Medicine (600216.SH) released the semi-annual report for 2024, during the reporting period the company achieved revenue of 4...
Zhejiang Medicine (600216.SH): achieved self-production of some important precursors of vitamins E and A.
Zhejiang Medicine (600216.SH) stated on the investor interaction platform on August 16 that the company has achieved self-production of some important precursors of Vitamin E and Vitamin A, realizing a high degree of integrated production of the above products.
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past WeekNo Data
